CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues
Revenues	$ 1,918	$ 2,027
Expenses
Selling, general and administrative	622	606
Research and development	127	112
Amortization of intangible assets	310	357
Goodwill impairments	0	469
Asset impairments, including loss on assets held for sale	8	148
Restructuring, integration, separation and IPO costs	13	12
Other expense (income), net	2	(30)
Total expenses	1,633	2,248
Operating income (loss)	285	(221)
Interest income	2	2
Interest expense	(362)	(368)
Loss on extinguishment of debt	0	(5)
Foreign exchange and other	(7)	1
Loss before provision for income taxes	(82)	(591)
Benefit from (provision for) income taxes	16	(16)
Net loss	(66)	(607)
Net income attributable to noncontrolling interest	(3)	(3)
Net loss attributable to Bausch Health Companies Inc.	$ (69)	$ (610)
Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.19)	$ (1.71)
Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)	$ (0.19)	$ (1.71)
Basic weighted-average common shares (in shares)	360.8	356.8
Diluted weighted-average common shares (in shares)	360.8	356.8
Product sales
Revenues
Revenues	$ 1,898	$ 2,003
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	543	564
Other revenues
Revenues
Revenues	20	24
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues	$ 8	$ 10